NeuroSense Therapeutics (NRSN) Expected to Announce Earnings on Tuesday

NeuroSense Therapeutics (NASDAQ:NRSN) is projected to release its results before the market opens on Tuesday, June 30th. Analysts expect NeuroSense Therapeutics to post earnings of ($0.1950) per share and revenue of $0.2680 million for the quarter.

NeuroSense Therapeutics Trading Down 1.9%

NeuroSense Therapeutics stock opened at $0.79 on Tuesday. NeuroSense Therapeutics has a 12 month low of $0.63 and a 12 month high of $2.35. The stock’s 50 day moving average is $0.78 and its 200-day moving average is $0.85. The company has a market capitalization of $25.69 million, a price-to-earnings ratio of -1.46 and a beta of 1.56.

Insider Buying and Selling

In related news, CFO Or Eisenberg acquired 250,000 shares of the stock in a transaction on Tuesday, June 16th. The shares were purchased at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the purchase, the chief financial officer directly owned 1,504,050 shares in the company, valued at approximately $1,203,240. The trade was a 19.94% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Alon Ben-Noon acquired 250,000 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was bought at an average cost of $0.80 per share, with a total value of $200,000.00. Following the completion of the acquisition, the chief executive officer directly owned 4,534,233 shares in the company, valued at approximately $3,627,386.40. This represents a 5.84% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 27.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Two Sigma Investments LP acquired a new position in NeuroSense Therapeutics in the third quarter valued at about $26,000. Squarepoint Ops LLC lifted its position in NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the period. Finally, Jane Street Group LLC bought a new stake in NeuroSense Therapeutics during the second quarter worth about $54,000. Institutional investors own 1.04% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on NRSN. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroSense Therapeutics in a report on Friday, May 8th. Roth Mkm assumed coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of NeuroSense Therapeutics in a report on Wednesday, April 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $8.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.